Log in
Enquire now
Neurophage Pharmaceuticals

Neurophage Pharmaceuticals

A company developing fusion-protein drug therapies to treat chronic neurodegenerative diseases, amyloidoses, Alzheimer’s and Parkinson’s diseases

OverviewStructured DataIssuesContributors

Contents

neurophage.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Consumer biotechnology
Consumer biotechnology
Biotechnology
Biotechnology
Technology
Technology
Biology
Biology
Neuroscience
Neuroscience
Location
Cambridge, Cambridgeshire
Cambridge, Cambridgeshire
Cambridge, Massachusetts
Cambridge, Massachusetts
AngelList URL
angel.co/neurophage...maceuticals
Legal Name
NeuroPhage Pharmaceuticals, Inc.
Number of Employees (Ranges)
11 – 50
Full Address
85 Bolton St, Cambridge, MA 02140, US
Investors
Shire (pharmaceutical company)
Shire (pharmaceutical company)
Merieux Equity Partners
Merieux Equity Partners
Founded Date
January 1, 2006
Total Funding Amount (USD)
17,000,000
Latest Funding Round Date
March 2014
Latest Funding Type
Series D
Series D
Wellfound ID
neurophage-pharmaceuticals
Country
United States
United States

Other attributes

Company Operating Status
Closed
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Neurophage Pharmaceuticals

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.